Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | WNT1 | P04628 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.40 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340642 | 0.91 | DRD2 (0.50) | MPOKCNH2IRAK1IRAK4CTSV | |
| SCHEMBL3335951 | 0.86 | HTR7 (0.53) | MPOKCNH2IRAK1IRAK4CTSV | |
| SCHEMBL17547081 | 0.81 | PFKFB3 (0.48) | MPODYRK1AKCNH2IRAK1IRAK4 | |
| SCHEMBL31182034 | 0.81 | PFKFB3 (0.48) | MPODYRK1AKCNH2IRAK1IRAK4 | |
| SCHEMBL3340159 | 0.78 | TAAR1 (0.46) | MPOKCNH2IRAK1IRAK4CTSV | |
| SCHEMBL30570082 | 0.77 | MPO (0.45) | MPODYRK1AKCNH2IRAK1IRAK4 | |
| SCHEMBL30570078 | 0.77 | MPO (0.45) | MPODYRK1AKCNH2IRAK1IRAK4 | |
| SCHEMBL16675749 | 0.77 | PRKCI (0.51) | MPODYRK1AWNT1GSK3BKCNH2 | |
| SCHEMBL18492830 | 0.77 | LOXL2 (0.51) | MPODYRK1AKCNH2IRAK1IRAK4 | |
| SCHEMBL16597444 | 0.77 | TEK (0.47) | MPODYRK1AKCNH2IRAK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013189588-A1 | HETEROCYCLYL-SUBSTITUTED-PHENYL DERIVATIVES FOR THE TREATMENT OF ERECTILE DYSFUNCTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2013-12-27 | — | — | WO | claimed |
| EP-2676954-A1 | Heterocyclyl-substituted-phenyl derivatives as vasodilators | Laboratorios del Dr. Esteve S.A. (ES) | 2013-12-25 | — | — | EP | claimed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | claimed |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2010-06-17 | — | — | US | claimed |
| EP-2148674-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | claimed |
| EP-2114894-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| WO-2008145335-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-04 | — | — | WO | claimed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | claimed |
| EP-1997807-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | claimed |
| WO-2008077625-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-07-03 | — | — | WO | claimed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | claimed |
| WO-2013189588-A1 | HETEROCYCLYL-SUBSTITUTED-PHENYL DERIVATIVES FOR THE TREATMENT OF ERECTILE DYSFUNCTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2013-12-27 | — | — | WO | disclosed |
| EP-2676954-A1 | Heterocyclyl-substituted-phenyl derivatives as vasodilators | Laboratorios del Dr. Esteve S.A. (ES) | 2013-12-25 | — | — | EP | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008077625-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-07-03 | — | — | WO | disclosed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | OPRL1, OPRM1, OPRK1 | MPO 1424/4885DYRK1A 1179/4885WNT1 3929/4885 |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | PKM, PKLR, HNMT | MPO 1379/4885DYRK1A 3434/4885WNT1 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.